Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer - Review of the literature

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 444-455

  Nelius, T ^a   Rinard, K ^a   Filleur, S ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen independent prostate cancer; Castration refractory prostate cancer; Hormone refractory prostate cancer; Metronomic chemotherapy Cyclophosphamide; Oral chemotherapy; Prostate cancer

Indexed keywords

CELECOXIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PREDNISONE; THALIDOMIDE; UFT;

ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEMORRHAGIC CYSTITIS; HUMAN; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; METRONOMIC CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PNEUMONIA; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; CASTRATION; CYCLOPHOSPHAMIDE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 79960999855     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.12.006     Document Type: Review

References (71)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424.
3. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
4. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
5. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
6. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
7. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007, 8:994-1000.
8. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
9. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
10. Galmarini C.M. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs 2009, 10:1359-1371.
11. Hussain A., DiPaola R.S., Baron A.D., et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009, 20:492-497.
12. Kelly W.K. Epothilones in prostate cancer. Urol Oncol 2009.
13. Rosenberg J.E., Ryan C.J., Weinberg V.K., et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009.
14. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556-563.
15. Attard G., Reid A.H., A'Hern R., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27:3742-3748.
16. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26:4563-4571.
17. Danila D.C., Morris M.J., de Bono J.S., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
18. Reid A.H., Attard G., Danila D.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28:1489-1495.
19. Yap T.A., Carden C.P., Attard G., de Bono J.S. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008, 8:449-457.
20. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
21. Aragon-Ching J.B., Dahut W.L. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009, 2:161-168.
22. Figg W.D., Arlen P., Gulley J., et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001, 28:62-66.
23. Sonpavde G., Periman P.O., Bernold D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21:319-324.
24. Chi K.N., Zoubeidi A., Gleave M.E. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 2008, 17:1955-1962.
25. Molife L.R., Attard G., Fong P.C., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010, 21:109-113.
26. Nelson J.B., Love W., Chin J.L., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487.
27. Tatarov O., Mitchell T.J., Seywright M., et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:3540-3549.
28. Higano C.S., Corman J.M., Smith D.C., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-984.
29. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
30. Slovin S.F., Kelly W.K., Wilton A., et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2009, 7:E77-E82.
31. Ziada A., Barqawi A., Glode L.M., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004, 60:332-337.
32. Lutsiak M.E., Semnani R.T., De Pascalis R., et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
33. Damber J.E., Vallbo C., Albertsson P., Lennernas B., Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006, 58:354-360.
34. Fontana A., Galli L., Fioravanti A., et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:4954-4962.
35. Raghavan D., Cox K., Pearson B.S., et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993, 72:625-628.
36. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
37. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
38. Man S., Bocci G., Francia G., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002, 62:2731-2735.
39. Shaked Y., Emmenegger U., Francia G., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005, 65:7045-7051.
40. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
41. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
42. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
43. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24.
44. Vacca A., Iurlaro M., Ribatti D., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94:4143-4155.
45. Witte L., Hicklin D.J., Zhu Z., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998, 17:155-161.
46. Bocci G., Nicolaou K.C., Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002, 62:6938-6943.
47. Yap R., Veliceasa D., Emmenegger U., et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005, 11:6678-6685.
48. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003, 100:12917-12922.
49. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003, 63:4342-4346.
50. Hermans I.F., Chong T.W., Palmowski M.J., Harris A.L., Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003, 63:8408-8413.
51. Di Lorenzo G., Autorino R., De Laurentiis M., et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007, 6:313-317.
52. Maulard-Durdux C., Dufour B., Hennequin C., et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996, 77:1144-1148.
53. Nelius T., Klatte T., de Riese W., Haynes A., Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2009.
54. Bracarda S., Tonato M., Rosi P., et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer 2000, 88:1438-1444.
55. Glode L.M., Barqawi A., Crighton F., Crawford E.D., Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003, 98:1643-1648.
56. Hellerstedt B., Pienta K.J., Redman B.G., et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 2003, 98:1603-1610.
57. Lord R., Nair S., Schache A., et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007, 177:2136-2140. discussion 40.
58. Nicolini A., Mancini P., Ferrari P., et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004, 58:447-450.
59. Nishimura K., Nonomura N., Ono Y., et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 2001, 60:49-54.
60. Wozniak A.J., Blumenstein B.A., Crawford E.D., et al. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer 1993, 71:3975-3978.
61. Slack N.H., Murphy G.P. Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 1984, 11:337-342.
62. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
63. Petrioli R., Fiaschi A.I., Francini E., Pascucci A., Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 2008, 34:710-718.
64. Oh W.K. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002, 1:81-89.
65. Nelius T., Klatte T., de Riese W., Haynes A., Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2010, 27:363-367.
66. Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009, 27:5431-5438.
67. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007, 25:669-674.
68. Sartor A.C., Oudard S., Ozguroglu M., Hansen S., Machiels J., Shen L., et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010, 28(Suppl.):15s. [abstr 4508].
69. Scher H.I., Beer T.M., Higano C.S., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
70. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
71. Rabascio C., Muratori E., Mancuso P., et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004, 64:4373-4377.